Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
eNq9WF1v2jAUfedXRHlPQmAddApUG2s3pFZjtGjTXiqTXMDMsVN/8LFfP4fQjU6OOkzdFyRs59xr3+Nzj5xcbHLirYALzGjPj8Om7wFNWYbpvOdP7q6Crn/RbyRLtEIHyzphM4xbvpcSJETPL2fDKSAqwu831x9Bfw/c7ze8hE2XkMon65TEJPyMxOIGFeUaL1kxnHk5yAXLen6h5G7US4TkOov+mvGfokApJNF+5HB2ef/mcDyJSrD/QFUC+DWicyMoUCvMVHEOVA6QhDnj25p821bYWIxBMMVTGCG5GHG2whlkxhAzRARYBZmts1vgKwKyDGIEj5ZpLqzA0RJtxvAwNCf9Xs8O5EYGzSDudOLzbrvb6rS7Z1ah+MFRmaugNxGl93GnGbe67QhotNX7ZtsgB4IoyyFogf4heE4hwAUmOFc5mlpWbsS4RMRRzbAYPKWdozgcHp7lRoZFQdA2XIrC9qgQR3oauBYHdxspd3DHtVwRfWb/4FNFSHRk1pO9mDjKuNSqAVNU1mjK1dj2IAaMStjUV9ROBuVmz0UM4uVgfzFqbgEjNSU4tRU8LUkKhJyMh/V693pS8QEJmHB3WvEN04ytxctr0GHNHWVf7GTUCFrwLL5vnXffxmdn1lfshyZYTXe6VJwVEGl1wuIU0RnSGTtVbjRnzVCPjH0lsu4cFEsRgRoPFVjqkmbpo+Vzdg/c3bFqwgj66fLOljxfFfDt7e6vERpnvT9ltxNtF51AU7U28eOJX91/J+5acbOuLKQsxLsoWq/X4QKJQCB9SuGMv3JXOGjT7py/Ey9QeaNKWR2lPq1a5nH1s72Hz7mFUx3w/vu90zbGkFzBCbWoJNuZsA4vX16r/9pfZ2mPnmiLuzA7q4okZtSVSVJTI+Jp3UHXlV5xLRBfZjNc8xJTy8skql6B+o0kKl+A+o3fXDMSMg==
3dSK1mrsJM4EjSqd
